About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 20 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 15 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation and SDC.direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
Featured
mRNA Technology Transfer Programme
12 April 2022Our Strategy
2023-2025
30 January 2023LAPaL
14 February 2022Access to Medicines Tracker
02 March 2020Our Strategy 2023-2025
Watch Greg Martin explain our new strategy that centres around five core goals for greater access to vital medicines and health technologies in lower- and middle-income countries. The Strategy also explains how these goals will be achieved, as well as outlining key MPP achievements since its inception in 2010.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in September 2023 (data as of 31 June 2023) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Interactive Map: Click here to view full size
Impact Stories
Dr Denise’s journey, from diagnosis to access to cancer care and treatment
“If I had remained in Nigeria 
, I would’ve died that year. ”
Dr Denise Ejoh, CEO of Cormode Cancer Foundation talks about her cancer journey, from diagnosis in Nigeria to treatment & care in England 
. 70% of death from cancer occur in low- and middle-income countries, one of the reasons being that people lack access to affordable treatment and care. At MPP, we believe in a world where millions of cancer deaths are preventable and where access to life-saving cancer treatments is equitable for all – no matter where you live.